A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy

NCT04570423 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors
Lymphoma

Interventions

DRUG: Eflapegrastim
DRUG: Chemotherapy

Sponsor

Spectrum Pharmaceuticals, Inc